09:59 AM EDT, 07/28/2025 (MT Newswires) -- AIM ImmunoTech ( AIM ) said Monday that midyear data from a phase 2 trial showed that Ampligen with AstraZeneca's ( AZN ) Imfinzi is "well-tolerated" in post-Folfirinox pancreatic cancer patients, with the combination treatment showing signs of no significant toxicity and better-than-expected survival data.

The company said about 21% of the patients enrolled in the trial as of the midyear report had progression-free survival beyond six months and 64% of eligible patients had overall survival beyond six months, which is better than expected in this setting.

Shares of AIM ImmunoTech ( AIM ) were over 154% higher in early Monday trading.

Price: 20.35, Change: +12.35, Percent Change: +154.38